Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Rating of “Hold” from Analysts

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has received a consensus recommendation of “Hold” from the five ratings firms that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $17.6667.

Several research firms recently issued reports on AUPH. Bloom Burton cut Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a report on Wednesday, November 5th. Jefferies Financial Group raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the stock from $10.00 to $21.00 in a research note on Friday, November 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $15.00 price objective (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 5th.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Aurinia Pharmaceuticals by 20.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 12,989 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 2,238 shares during the period. Vanguard Personalized Indexing Management LLC raised its holdings in Aurinia Pharmaceuticals by 27.2% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 13,892 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 2,973 shares during the period. BNP Paribas Financial Markets lifted its position in Aurinia Pharmaceuticals by 32.4% during the second quarter. BNP Paribas Financial Markets now owns 13,034 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 3,191 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Aurinia Pharmaceuticals by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock worth $642,000 after buying an additional 3,497 shares during the period. Finally, Creative Planning increased its position in shares of Aurinia Pharmaceuticals by 21.0% in the second quarter. Creative Planning now owns 20,699 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 3,594 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Up 0.3%

NASDAQ:AUPH opened at $16.17 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. The company’s fifty day moving average price is $13.31 and its 200-day moving average price is $11.05. Aurinia Pharmaceuticals has a 1-year low of $6.55 and a 1-year high of $16.48. The firm has a market capitalization of $2.13 billion, a P/E ratio of 37.61 and a beta of 1.30.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.07. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Aurinia Pharmaceuticals will post 0.11 EPS for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.